PROJECT 007 ? CANCER EPIDEMIOLOGY RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT Cancer is a major cause of morbidity and mortality in the United States and many other countries around the world. The Cancer Epidemiology Research Program (CE), directed by Xiao-Ou Shu, MD, PhD, and Wei Zheng, MD, PhD, conducts high-impact research to improve the understanding of cancer etiology and identify biomarkers for cancer risk and prognosis to inform the development of effective cancer prevention strategies. The mission of CE is to create an optimal environment to facilitate the interaction and collaboration of investigators conducting cancer epidemiology research, and to train the next generation of scientists.
The specific aims of CE are to: 1) identify biomarkers for cancer risk assessment and early detection; 2) identify nutrition, lifestyle, and other environmental factors affecting cancer risk; 3) investigate biomarkers and lifestyle factors for cancer prognoses; and 4) identify determinants of health disparities in cancer incidence and mortality. One of the key strengths of CE lies in the establishment and conduct of three large cohort studies with extensive exposure data and biospecimens obtained from 223,000 study participants. CE members also conduct large cancer case-control studies and intervention trials and play major leadership roles in the Vanderbilt DNA Databank (BioVU), which contains extensive electronic health records and DNA samples collected from ~250,000 patients. Recently, CE members helped launch the national All of Us Research Program with a goal to enroll one million participants across the US and lead its Data and Research Support Center. These resources have provided, and will continue to provide, extraordinary population-based field laboratories for scientific discoveries. CE members are at the forefront of identifying genetic and lifestyle factors and biomarkers for the risk and progression of multiple cancers, with research that has significantly advanced our knowledge of cancer etiology and contributed to the modification of multiple guidelines and recommendations for cancer prevention. Most of the research within CE focuses on cancers that are directly relevant to the Vanderbilt-Ingram Cancer Center catchment area, and involves participation by multiple segments of this population, including historically underrepresented groups. CE members play a leadership role in multiple large cancer epidemiology consortia and direct large international studies to test scientific hypotheses that cannot be adequately investigated in US- based studies. CE hosts five NIH-funded training programs and has successfully fostered the career development of more than 10 junior investigators. There are 24 program members from six departments and two schools, with $13.5M in total peer-reviewed funding and NCI making up 67% ($9.0M). Out of 586 publications, 53% are intra-programmatic and 18% are inter-programmatic. Members also have 387 collaborative publications with investigators at other NCI-designated cancer centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA068485-25
Application #
10024650
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1998-09-01
Project End
2025-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
25
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Pannala, Venkat R; Wall, Martha L; Estes, Shanea K et al. (2018) Metabolic network-based predictions of toxicant-induced metabolite changes in the laboratory rat. Sci Rep 8:11678
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Doxie, Deon B; Greenplate, Allison R; Gandelman, Jocelyn S et al. (2018) BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res 31:708-719
Salisbury-Ruf, Christi T; Bertram, Clinton C; Vergeade, Aurelia et al. (2018) Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study. Elife 7:
Laroumanie, Fanny; Korneva, Arina; Bersi, Matthew R et al. (2018) LNK deficiency promotes acute aortic dissection and rupture. JCI Insight 3:
Burns, Michael C; Howes, Jennifer E; Sun, Qi et al. (2018) High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Anal Biochem 548:44-52
Phelps, Hannah M; Al-Jadiry, Mazin F; Corbitt, Natasha M et al. (2018) Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq. World J Pediatr 14:585-593
Liu, Qi; Herring, Charles A; Sheng, Quanhu et al. (2018) Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biol 16:e2006687
Almodovar, Karinna; Iams, Wade T; Meador, Catherine B et al. (2018) Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol 13:112-123

Showing the most recent 10 out of 2462 publications